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Reactive oxygen species might be removed or inactivated by diet-de-
rived (exogenous) antioxidants. The aim of this study was to investigate 
whether a diet rich in red beetroot products would affect the antioxidant 
capacity of human plasma.
Methods: A randomized, study was executed in group of fifteen obese 
women, age 65y (+/-4y), suffered from ischemic heart disease (IHD). All 
subjects received during 6 weeks red beetroot juice or fat free beetroot 
crisps in determined daily portions. Nutritional status (body composi-
tion, skinfold thickness), and lipid profile were estimated before and af-
ter dietetic intervention as well as concentration in plasma Total Antioxi-
dants Status (TAS). The nutritional value of the daily diet (antioxidants 
vitamins, saturated fatty acids supply), was controlled during the whole 
intervention period by 24h recall.
Results: The six weeks long administration of red beetroot products, 
caused a significant increase TAS about 11%. No changes in nutritional 
status parameters and nutritional density of diets (antioxidants vitamins, 
fat supply) were observed.
Conclusions: Daily intake selected beetroot products can significantly 
improve the plasma antioxidant capacity of obese, suffered from IHD 
women.
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Introduction: The melanocortin-4 receptor (MC4R) is part of an impor-
tant pathway regulating energy balance. In a previous study, we have 
demonstrated that the generation of antibodies (Abs) against the N-ter-
minal domain of the MC4R in rats induced a mild obese phenotype as-
sociated with insulin resistance. These findings prompted us to search for 
functional anti-MC4R autoAbs in sera of obese patients. 
Methods: Auti-MC4R autoAbs were detected after screening sera from 
216 patients with different body mass index (BMI) by using direct and 
inhibition ELISA with an N-terminal sequence of the MC4R. Binding to 
the native MC4R was evaluated by flow cytometry with HEK-293 cells 
expressing the human MC4R and pharmacological properties of the au-
toAbs were assessed by measuring adenylyl cyclase activity. 
Results: Positive results in all tests were obtained in 5 patients with over-
weight or obesity (prevalence: 3.6%) but not in normal weight patients. 
The selective binding properties of the anti-MC4R autoAbs were con-
firmed by surface plasmon resonance and immunoprecipitation with the 
native MC4R. Moreover it was demonstrated that these autoAb acted as 
non-competitive antagonists in vitro. One of these autoAbs was evalu-
ated in vivo and increased food intake in rats after passive transfer via 
intracerebroventricular injection. 
Conclusion: The fact that functionally active autoAbs were only present 
in overweight and obese but not in normal weight subjects strongly sug-
gests a possible pathogenic role. Such inhibitory anti-MC4R autoAbs 
might therefore contribute to the development of obesity in a small sub-
population of patients.
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Introduction: Tungstate has proved to be a novel antiobesity agent, act-
ing on energy expenditure and body weight gain through leptin pathway, 
and modifying brain neuropeptide levels. Based on these results we in-
vestigated the molecular targets of tungstate on the CNS.
Methods: A hypothalamic cell line was cultured with or without leptin, 
tungstate, MAPK and JAK2 inhibitors (including overexpression of 
SOCS3). We analyzed gene and protein expression, and intracellular lo-
cation of different leptin pathway proteins. We administrated tungstate 
to wistar rats by ICV at the 3V as an in vivo model. We performed pro-
teomic analysis from isolated hypothalamic nucleus (ARC, LHA and 
PVN) using obese/control mice, treated or not with oral tungstate. 
Results: In-vitro, tungstate treatment increases P-JAK2 (2,5 fold, p<0,05), 
but does not alter the P-Tyrosine-STAT3. Treatment also increases P-
ERK (7,6 fold, p<0,001) and P-Serine-STAT3 (2,6 fold, p<0,01), favour-
ing its accumulation in the nucleus (1,8 fold) to induce gene expression.
Tungstate ICV administration entails a 27,6% food intake reduction and 
a 25,6% body weight gain reduction. Proteome analysis of hypothalamic 
nucleus showed different protein expression profile between lean/obese 
and W treated/non-treated animals.
Conclusions: We have identified ERK in the leptin pathway as the molecu-
lar tungstate target in neural cells. This increase in P-MAPK induces an in-
crease in P-Serine-STAT3, modulating gene expression. Tungstate admin-
istration decreases food intake and body weight gain (ICV) and modifies 
hypothalamic protein expression profile. As a whole, these results demon-
strate a direct central effect of tungstate modulating energy homeostasis.
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Introduction: Childhood obesity is associated with increased cardi-
ometabolic risk. Several risk factors have been described, namely homo-
cysteine plasma levels. 
Methods: 56 children (29 boys; 27 girls; BMI>95th percentile) between 
7-9 year-old participated in a lifestyle intervention program. Assessment 
at baseline included weight, height, BMI, BMI-Zscore (BMI-Zs), waist 
circumference (WC), Tanner stage, blood pressure (systolic (SBP) and di-
astolic (DBP)) and fasting serum level of glucose, insulin, C-peptide, total 
cholesterol, HDL, LDL, triglycerides (TG), leptin, interleukin 6 (IL-6), ho-
mocysteine and folic acid. Insulin resistance (IR) was calculated by FGIR 
method. Results with statistical significance (p<0.05) are presented.
Results: At baseline, all children presented with abdominal obesity 
(WC≥90th percentile). IR (FGIR<6) was observed in 9% of children and 
40% showed hypertension. Total cholesterol ≥180 mg/dl and TG≥100 
mg/dl were found in 36% and 16%, respectively. Correlation analysis 
showed a linear relationship between BMI and the following variables: 
SBP, insulin, C-peptide, IR, leptin and TG. WC correlated positively with 
BMI, BMI-Zs, SBP, C-peptide, insulin, IR, leptin and homocysteine, and 
negatively with folic acid. IR correlated linearly with SBP, C-peptide, TG, 
leptin and homocysteine, and inversely with folic acid. The plasma levels 
of homocysteine showed a positive correlation with weight, insulin, C-
peptide, leptin, IL-6 and TG. However, folic acid levels were inversely cor-
related with homocysteine, BMI, DBP, insulin, C-peptide, leptin and TG.
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Conclusions: These obese children showed a significant prevalence of dy-
slipidemia, IR and hypertension, which were correlated with higher ho-
mocysteine levels. In contrast, folic acid seems to have a protective role. 
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Introduction: Dietary carbohydrates have been shown to impact lipid 
metabolism and cardiovascular disease (CVD) risk. The objectives of 
this study were to compare the effects of high vs low glycaemic diets on 
plasma lipids and genes involved in hepatic lipid metabolism in rats with 
dietary-induced obesity (DIO). 
Methods: Male Sprague-Dawley rats (n=45) with established DIO were 
divided into 4 groups and fed low glycaemic amylose (AMO) or high 
glycaemic amylopectin (AMN) starch diets in an ad libitum or energy-
restricted (ER) paradigm for 4 weeks. At the end of the experiment, 
overnight-fasted rats were killed, and blood and liver were harvested for 
serum lipid and gene expression analyses. 
Results: AMO led to lower serum concentrations of triglycerides, total 
and HDL-cholesterol than AMN, but only when rats were fed ad libi-
tum (p<0.05). Semi-quantitative RT-PCR showed lower relative mRNA 
levels for 7α-hydroxylase in the liver of rats fed ad libitum vs ER-AMN 
(p<0.05). On the other hand, relative levels of the LDL-receptor mRNA 
were higher in ER vs ad libitum feeding, independent of the diet (p<0.01). 
The type of starch did not affect relative mRNA levels of HMG-CoA 
reductase or fatty acid synthase. Western blot analyses of hepatic lipo-
protein receptors are in progress.
Conclusions: A low glycaemic diet improves lipid metabolism under 
free feeding conditions, but has no advantage over a high glycaemic diet 
when energy intake is restricted. Differences in relative mRNA levels of 
genes involved in hepatic lipid metabolism account only partly for the 
benefits of the low glycaemic diet. 
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Background: An excess in protein intake could lead to obesity and surely 
overload the immature renal function of the infant. A formula with the 
protein ratio of 1,2g/100ml confirmed its efficacy and tolerance in a clini-
cal trial(Turck et al. JPGN 2006, 43:364-371). Several studies have en-
lightened the positive role of the lactose on colic flora and absorption of 
micronutriments. 
Objectives: To evaluate a new infant formula with a carbohydrate frac-
tion of 100% lactose and 1,2g/100ml proteins. 
Methods: On term new-borns (< 7 days) were randomized to receive un-
til the end of the 4th month(M4) exclusively, the studied formula (Group 
L )with 7,5 g/100 ml lactose, or the former formula (Nidal Novaïa 1®, 
Group N) with 6,4g/100ml lactose and 1,1g/100ml maltodextrin. Both 
formulas are otherwise strictly identical. Formula L’s non inferiority was 
evaluated with the average daily weight (ADW) variation by an ANCO-
VA analysis of the Per Protocol (PP) population. Tolerance was assessed 
as secondary criteria on the Intention To Treat population (ITT). 
Results: Were included 184 newborns(ITT=178 infants; PP=137 infants). 
ADW was under the non inferiority range (+/-2.5g/d). The daily intake 
in ml/kg was significantly lower in the group L (ITT =-5.28ml/d/kg; 
p<0.007). Frequency of undesirable events including transit disorders 
were similar in the two groups. 
Conclusions: These results validate the efficacy and tolerance of this for-
mula and prove that a formula should be seen in its globality. Protein 
and carbohydrate changes of the formula leads each time to lower intake 
suggesting a better proteino-energetic use.
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Introduction: Polyunsaturated fatty acids (PUFAs) composition of neu-
ral membranes is a key factor for brain development and function in-
cluding cognition.
Methods: In rat studies supplementation and moderate deficiency of 
PUFAs were maintained during fetal development and early postnatal 
age and their impact on fatty acid composition of different phospholi-
pids and on behavioural development and cognition ability up to old 
age were followed. Four ages were compared: 12th postnatal day, puberty, 
adult (12-month) and old (28-month) ages. Fatty acids were determined 
by gas chromatography. Spatial learning behaviour in Morris water maze 
was tested in the adult and 28 months old ages and behavioural stress 
sensitivity was also investigated at the adult age.
Results: As a result of PUFA supplementation the content of n-3 docosa-
hexaenoic acid (DHA) increased in most of the phospholipid fractions 
starting from the age of 12 days up to the one year old adult age. By 
the old age no difference in the fatty acid composition of nervous tissue 
membranes were detected any more between groups, however behav-
ioural effect could be found even in the 28 months old age. The PUFA 
supplementation improved spatial learning, while the moderate PUFA 
deficiency acted into the opposite direction in cognition and decreased 
resistance against psychic stress.
Conclusion: Both the supplementation and the deficiency of PUFAs 
during development have long-term effect on fatty acid composition of 
nervous tissue membrane phospholipids up to adult age, but the func-
tional consequences on cognition lasted even longer up to the old age of 
28 months. Supported by Hungarian Scientific Research Fund (OTKA) 
K68875 and Ministry of Health Research Grant (ETT) 21/2006 to CN
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Introduction: The expression of total leptin receptor (Ob-R) and the 
long-signalling form (Ob-Rb) were measured by real time RT-PCR in 
PBMC to determine whether changes could be detected with obesity 
and ageing in humans. 
Methods: Blood was sampled from lean (n= 8; BMI, 20-26 kg.m-2) and 
obese (n= 5; BMI 30-36 kg.m-2) young (23-38 years) men as well as lean 
(n= 9; BMI, 20-26 kg.m-2) and obese (n= 7; BMI 30-36 kg.m-2) older men 
(50-64 years). Reverse transcribed cDNA from PBMC cells was ampli-
